✨
AI Summary
- FDA's novel drug review speed remained steady in 2025.
- Analysis of the loss of 'fast approvals' and reviewer performance.
- Concerns about potential 2026 impact from staff departures.
Guests on This Episode
BS
Bridget Silverman
4 podcast appearances
DG
Derrick Gingery
8 podcast appearances
NH
Nielsen Hobbs
8 podcast appearances
SS
Sue Sutter
8 podcast appearances